Galmed Pharmaceuticals Ltd.
GLMDGalmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for liver diseases. The company's lead product candidate, Aramchol, is a bile acid derivative developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Galmed also explores other therapeutic options targeting liver and metabolic conditions.
Company News
Galmed Pharmaceuticals reported significant bioavailability results for Aramchol meglumine, showing 3-5 fold increase compared to previous tablets, potentially enabling once-daily dosing and reducing drug costs.
Galmed Pharmaceuticals plans to invest up to $10 million in digital assets, engaging Tectona Ltd. to manage a new crypto treasury strategy aimed at enhancing capital efficiency and shareholder value.
Galmed Pharmaceuticals has launched a collaboration with Virginia Commonwealth University to investigate its drug Aramchol's potential in overcoming drug resistance in gastrointestinal cancers, including colorectal and liver cancers.
Galmed Pharmaceuticals has identified novel pharmacodynamic blood markers for its lead compound Aramchol, which provide insights into the drug's potential beyond NASH treatment, including its impact on cardiometabolic and fibrotic conditions.
Mainz Biomed shares jumped 16% in pre-market trading after the company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test. Several other stocks also saw significant pre-market movement.
